<p><strong>Intravenous-</strong><br />
Neutropenia following bone marrow transplantation:</p>

<ul>
	<li><strong>Adult:</strong>&nbsp;19.2 million IU/m2&nbsp;or 150 mcg/m2&nbsp;daily by IV infusion started the day after transplantation for a maximum of 28 consecutive days.</li>
	<li><strong>Child:</strong>&nbsp;&gt;2 yr: 19.2 million IU/m2&nbsp;or 150 mcg/m2&nbsp;daily by IV infusion started the day after transplantation for a maximum of 28 consecutive days.</li>
</ul>

<p><strong>Subcutaneous-</strong><br />
Mobilisation of peripheral blood progenitor cells for autologous peripheral blood stem cell transplantation:</p>

<ul>
	<li><strong>Adult:</strong>&nbsp;As monotherapy: 1.28 million IU/kg or 10 mcg/kg daily for 4-6 days (5-6 days in healthy donors). Following adjunctive myelosuppressive chemotherapy: 19.2 million IU/m2&nbsp;or 150 mcg/m2&nbsp;daily, started the day after completion of chemotherapy for a maximum of 28 consecutive days.</li>
</ul>

<p><strong>Subcutaneous-</strong><br />
Chemotherapy-induced neutropenia:</p>

<ul>
	<li><strong>Adult:</strong>&nbsp;19.2 million IU/m2&nbsp;or 150 mcg/m2&nbsp;daily, start the day after completion of chemotherapy for a maximum of 28 consecutive days.</li>
</ul>